From: PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials
All population (n = 384) | |||||
---|---|---|---|---|---|
ORR | NPR | ||||
15.1 | 58.5 | ||||
95% CI 8.6% ; 25.1% | 95% CI 44.4% ; 71.3% | ||||
Efficacy by histological subtype | |||||
Histological subtype | N patients | ORR | NPR | ||
% | 95% CI | % | 95% CI | ||
UPS | 103 | 15.7 | 7.5-30.0 | 50.5 | 39.0-61.9 |
LMS | 82 | 6.9 | 2.0-21.3 | 54.1 | 29.3-77.0 |
DDLPS | 61 | 7.3 | 1.2-33.7 | 54.5 | 24.5-81.6 |
ASPS | 41 | 48.8 | 26.0-72.0 | 80.5 | 54.1-93.5 |
Others | 97 | 10.3 | 5.0-20.2 | 52.1 | 35.5-68.3 |
Efficacy by the therapeutic strategy | |||||
PD1/PD-L1 single agent | 153 | 18.7 | 2.1-71.6 | 63.6 | 25.3-90.0 |
Combination with other immunotherapy | 114 | 11.4 | 3.5-31.4 | 57.9 | 18.2-89.4 |
Combination with non-immunological agent | 117 | 14.0 | 0.5-84.2 | 53.8 | 7.9-94.0 |